ArticlePloS one2025
Burden of chronic obstructive pulmonary disease in adults aged 70 years and older, 1990-2021: Findings from the Global Burden of Disease Study 2021.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Personality Traits, Illness Acceptance, and Psychosocial Outcomes in Patients with Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study.Journal of clinical medicine · 2026Article
- Uncovering sodium overload-associated gene signatures in chronic obstructive pulmonary disease through integrated bioinformatics and machine learning.Journal of thoracic disease · 2026Article
- The Effect of Tele-nursing Education on Medication Adherence and Health Literacy in COPD patients.BMC nursing · 2026Article
- Global trends and inequalities in environmental risk-attributable chronic obstructive pulmonary disease mortality among adults aged 80+ years, 1990-2021: an analysis of the Global Burden of Disease Study 2021.Journal of thoracic disease · 2026Article
- Temporal trends in mortality involving chronic lower respiratory disease and chronic kidney disease: evidence from CDC WONDER, 1999-2023.BMC nephrology · 2026Article
- Global, regional, and national burden of chronic obstructive pulmonary disease and asthma from 1990 to present: risk attributions and projections to 2050.Internal and emergency medicine · 2026Article
- Associations between physical activity and mortality in chronic obstructive pulmonary disease population with comorbidities: a prospective cohort.Journal of thoracic disease · 2026Article
- Frailty, depressive symptoms, and incident respiratory disease: a CHARLS cohort study.BMC pulmonary medicine · 2026Article
- Declining yet persistent asthma mortality among U.S. adults aged 65 years and older (1999-2020).Frontiers in medicine · 2026Article
- Integrated Care for COPD in the Elderly: Impact on Healthcare Utilization Across Healthcare Settings.International journal of chronic obstructive pulmonary disease · 2026Article
- Luteolin: exploring its therapeutic potential and molecular mechanisms in pulmonary diseases.Frontiers in pharmacology · 2025Review
- Targeting Multiple Pathophysiological Axes in COPD: Nanomaterial Advances.International journal of nanomedicine · 2025Review
- Effect of nurse-led interventions on dyspnea severity and psychological well-being among patients with chronic obstructive pulmonary disease.Bioinformation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLife expectancy at age 70 has continued to rise globally over the past 30 years. However, a comprehensive assessment of the burden of COPD in older adults is lacking. We aimed to estimate the burden of COPD and its attributable risk factors among adults aged ≥70 years.
methodsData on the prevalence, incidence, deaths, disability-adjusted life years (DALYs), and risk factors of COPD among adults aged ≥70 years from 1990 to 2021 across 204 countries and territories, were sourced from the Global Burden of Disease Study 2021. Estimated annual percentage change (EAPC) was used to illustrate temporal trends at global and regional levels from 1990 to 2021.
resultsIn 2021, the global numbers of prevalent and incident COPD cases among older adults were 99.7 and 7.4 million, increasing by 162.2% and 157.4% from 1990. The prevalence and incidence rates increased from 18823.5 (95% uncertainty interval (UI) 16324.4-21208.4) to 20165.6 (17703.8-22549.4) and 1429.0 (1224.2-1613.0) to 1502.7 (1309.0-1677.9) per 100,000 population (EAPC 0.31, 95% CI 0.28-0.33; 0.17, 95% CI 0.16-0.19). The global numbers of COPD-associated deaths and DALYs in 2021 reached 2.9 and 45.4 million, increasing by 70.7% and 70.0% from 2019, while the corresponding rates declined (both EAPC <0). The highest prevalence and the largest increase in incidence rate occurred in high sociodemographic index (SDI) regions, while the largest increase in death and DALY rates occurred in the low SDI regions. The United States had the highest prevalence rates in 2021, while Iran had the largest increase. From 1990 to 2021, the death rates attributable to ambient ozone pollution-related COPD in older adults have risen, particularly in low and low-middle SDI regions.
conclusionCOPD in older adults has progressively become a global health challenge with rising prevalence and incidence rates. Although the death and DALY rates attributed to COPD have globally decreased in older adults, the absolute counts are rapidly increasing. The inequalities across different regions and countries underscore a multi-faceted approach to COPD management in older adults.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.